Vertex's Revenue Surges but EPS Slips

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.Vertex Pharmaceuticals(VRTX 0.14%), known for its innovative treatments, reported its fourth-quarter earnings on Feb. 10. The company's revenue increased significantly to $2.91 billion, which was above analysts' expectations of $2.78 billion. This top-line improvement was largely due to the continued success of its cystic fibrosis lineup, particularly Trikafta/Kaftrio. However, non-GAAP earnings per ...